STOCKHOLM, Sweden, Oct. 4, 2004 (PRIMEZONE) -- The contract between Artimplant and Molnlycke Health Care concerning development and licensing of products for wound healing has been terminated.
"Artimplant's biomaterial Artelon has been tested over several years by Molnlycke Health Care with the aim of developing products for the treatment of deep wounds. Artimplant's technology is very promising, but in consultation with Artimplant, we have chosen to terminate the project to focus on other prioritized projects," says Anders Husmark, Vice President, Business Area Wound Care at Molnlycke Health Care.
"We are of course disappointed that we cannot continue the project. However, possibilities are now created for Artimplant to use the results of the development and seek other ways of commercializing the Artelon platform for wound applications," says Tord Lendau, Artimplant's CEO.
In the short term, the termination of the cooperation has no financial implications for Artimplant.
Artimplant continues to further develop these products with focus on applications for esthetic and reconstructive surgery.
For additional information, please contact: Tord Lendau, CEO, phone +46 (0)31 746 56 00, +46 (0)708 369 403, tord.lendau@artimplant.se Web site: www.artimplant.com
Artimplant's mission is to develop novel biodegradable materials and implants that meet the needs of patients, physicians and healthcare providers in orthopedics and other therapy areas. The company works together with global partners as a center of excellence in this development.
Artimplant's vision is to become the partner of choice in biomaterials for hard and soft tissue repair in multiple therapy areas. Artimplant is a public company, listed on the Stockholm Exchange, O-list.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2004/10/04/20041004BIT22640/wkr0001.pdf
-0-